Dean Investment Associates’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.28M Sell
94,713
-6,482
-6% -$170K 0.3% 138
2026
Q1
$2.84M Buy
101,195
+6,465
+7% +$172K 0.4% 126
2025
Q4
$2.36M Sell
94,730
-20,550
-18% -$518K 0.34% 134
2025
Q3
$2.94M Sell
115,280
-4,671
-4% -$115K 0.41% 125
2025
Q2
$2.91M Buy
119,951
+3,061
+3% +$71.4K 0.43% 119
2025
Q1
$2.96M Buy
116,890
+20,166
+21% +$528K 0.44% 108
2024
Q4
$2.57M Sell
96,724
-35,109
-27% -$952K 0.37% 139
2024
Q3
$3.82M Sell
131,833
-7,618
-5% -$222K 0.52% 68
2024
Q2
$3.9M Sell
139,451
-5,413
-4% -$149K 0.55% 69
2024
Q1
$4.02M Sell
144,864
-1,158
-0.8% -$32.1K 0.55% 77
2023
Q4
$4.2M Sell
146,022
-7,688
-5% -$232K 0.6% 61
2023
Q3
$5.1M Buy
153,710
+15,778
+11% +$558K 0.84% 28
2023
Q2
$5.06M Buy
137,932
+4,110
+3% +$160K 0.82% 34
2023
Q1
$5.46M Buy
133,822
+14,745
+12% +$637K 0.87% 31
2022
Q4
$6.1M Sell
119,077
-1,492
-1% -$71.5K 1.04% 14
2022
Q3
$5.28M Buy
120,569
+2,222
+2% +$108K 1.08% 10
2022
Q2
$6.21M Sell
118,347
-1,979
-2% -$101K 1.21% 6
2022
Q1
$6.23M Sell
120,326
-968
-0.8% -$50.2K 1.12% 8
2021
Q4
$7.16M Sell
121,294
-169
-0.1% -$8.37K 1.26% 3
2021
Q3
$5.22M Sell
121,463
-410
-0.3% -$18.2K 0.98% 15
2021
Q2
$4.77M Buy
121,873
+24,618
+25% +$957K 0.88% 20
2021
Q1
$3.52M Sell
97,255
-2,041
-2% -$72.5K 0.66% 40
2020
Q4
$3.65M Sell
99,296
-9,049
-8% -$332K 0.76% 36
2020
Q3
$3.77M Sell
108,345
-2,012
-2% -$70.5K 0.9% 17
2020
Q2
$3.42M Buy
110,357
+3,427
+3% +$116K 0.82% 27
2020
Q1
$3.31M Sell
106,930
-2,258
-2% -$76.9K 0.71% 43
2019
Q4
$4.06M Sell
109,188
-45,282
-29% -$1.61M 0.64% 56
2019
Q3
$5.27M Buy
154,470
+6,963
+5% +$253K 0.77% 39
2019
Q2
$6.06M Sell
147,507
-9
-0% -$357 0.87% 22
2019
Q1
$5.94M Sell
147,516
-89
-0.1% -$3.56K 0.86% 27
2018
Q4
$6.11M Buy
147,605
+3,144
+2% +$131K 0.97% 21
2018
Q3
$6.04M Sell
144,461
-41,537
-22% -$1.6M 0.84% 34
2018
Q2
$6.4M Sell
185,998
-4,497
-2% -$154K 0.95% 22
2018
Q1
$6.41M Sell
190,495
-4,552
-2% -$156K 0.95% 24
2017
Q4
$6.7M Buy
195,047
+1,391
+0.7% +$47.4K 1.02% 12
2017
Q3
$6.56M Buy
193,656
+10,027
+5% +$322K 1% 19
2017
Q2
$5.85M Buy
183,629
+29,556
+19% +$932K 0.89% 30
2017
Q1
$5M Buy
154,073
+122,566
+389% +$3.86M 0.84% 42
2016
Q4
$971K Buy
31,507
+2,952
+10% +$90.1K 0.17% 134
2016
Q3
$918K Buy
28,555
+2,095
+8% +$70.1K 0.17% 126
2016
Q2
$884K Buy
26,460
+1,043
+4% +$33.3K 0.17% 125
2016
Q1
$715K Buy
25,417
+999
+4% +$28.5K 0.15% 147
2015
Q4
$748K Buy
24,418
+159
+0.7% +$5K 0.17% 132
2015
Q3
$723K Buy
24,259
+1,350
+6% +$43.3K 0.16% 135
2015
Q2
$729K Buy
22,909
+779
+4% +$25.4K 0.17% 148
2015
Q1
$731K Buy
22,130
+1,774
+9% +$56.4K 0.17% 146
2014
Q4
$602K Buy
20,356
+884
+5% +$25.3K 0.14% 154
2014
Q3
$546K Buy
19,472
+610
+3% +$17.1K 0.13% 155
2014
Q2
$531K Buy
18,862
+352
+2% +$10K 0.12% 157
2014
Q1
$564K Buy
18,510
+911
+5% +$27.2K 0.14% 143
2013
Q4
$511K Buy
17,599
+1,099
+7% +$32K 0.12% 156
2013
Q3
$450K Buy
16,500
+1,761
+12% +$47.9K 0.12% 151
2013
Q2
$392K Buy
+14,739
New +$407K 0.11% 161

Other funds holding PFE

Dean Investment Associates's PFE Position: Q2 2026 in Review

Dean Investment Associates reduced its Pfizer (PFE) stake by 6.4% in Q2 2026, selling an estimated $170K and leaving 94,713 shares worth $2.28M. The position accounts for 0.3% of the portfolio, ranked #138.

Dean Investment Associates first reported a position in PFE in Q2 2013 and has held it in 53 quarters since. The position peaked at $7.16M in Q4 2021. 2,823 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • Dean Investment Associates held 94,713 shares of Pfizer worth $2.28M as of Q2 2026.
  • Dean Investment Associates sold 6,482 Pfizer shares in Q2 2026, an estimated $170K.
  • Pfizer made up 0.3% of Dean Investment Associates's portfolio in Q2 2026, its #138 holding.
  • Dean Investment Associates first reported a position in Pfizer in Q2 2013 and has held it in 53 quarters since.
  • Dean Investment Associates's Pfizer position peaked at $7.16M in Q4 2021.
  • 2,823 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on Dean Investment Associates's 13F filing for Q2 2026, filed 14 Aug 2026.